Nkarta, Inc. Peo Actually Paid Comp Amt
Nkarta, Inc. (NKTX) reported Peo Actually Paid Comp Amt of $2.04 million for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-23.
Financial Statements › Cash Flow › Other Cash Flow Items
ecd:PeoActuallyPaidCompAmt · last filed 2026-04-23
| Period end | Peo Actually Paid Comp Amt 12 month |
|---|---|
| 2025-12-31 | $2.04M DEF 14A · filed 2026-04-23 |
| 2024-12-31 | $1.54M DEF 14A · filed 2026-04-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |